Published in Oncologist on October 01, 2007
The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet (2009) 9.68
FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol (2010) 8.73
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32
Challenges of antibacterial discovery. Clin Microbiol Rev (2011) 3.94
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Leukaemogenesis: more than mutant genes. Nat Rev Cancer (2010) 2.16
The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology. Physiol Rev (2012) 1.95
Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One (2010) 1.95
Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem (2011) 1.88
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem (2012) 1.74
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A (2008) 1.73
Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses (2009) 1.66
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol (2008) 1.59
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One (2010) 1.58
Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. Cancer Discov (2012) 1.56
Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev (2009) 1.55
The functional significance of microRNA-145 in prostate cancer. Br J Cancer (2010) 1.48
Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci U S A (2009) 1.46
Redundant control of adipogenesis by histone deacetylases 1 and 2. J Biol Chem (2010) 1.33
Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med (2011) 1.30
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res (2011) 1.30
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone (2011) 1.30
Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. J Nat Prod (2011) 1.30
Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26
Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J Am Chem Soc (2011) 1.26
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules (2015) 1.25
Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res (2009) 1.25
Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res (2009) 1.19
Activation and inhibition of histone deacetylase 8 by monovalent cations. J Biol Chem (2009) 1.18
Progranulin: a growth factor, a novel TNFR ligand and a drug target. Pharmacol Ther (2011) 1.16
Targeting Huntington's disease through histone deacetylases. Clin Epigenetics (2011) 1.13
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer (2010) 1.13
A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Elife (2014) 1.12
Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation. Sci Rep (2012) 1.11
Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood (2011) 1.09
Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. Chem Biol (2010) 1.09
Use of epigenetic drugs in disease: an overview. Genet Epigenet (2014) 1.08
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget (2015) 1.08
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res (2010) 1.08
Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. Oncotarget (2015) 1.08
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer (2010) 1.07
Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells. J Med Chem (2008) 1.07
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol (2015) 1.06
A proposal regarding reporting of in vitro testing results. Clin Cancer Res (2013) 1.06
Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One (2011) 1.05
Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol (2013) 1.04
Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. J Cell Mol Med (2009) 1.03
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans. EMBO J (2010) 1.03
HDAC3 is essential for DNA replication in hematopoietic progenitor cells. J Clin Invest (2013) 1.02
HDAC inhibition and graft versus host disease. Mol Med (2011) 1.02
The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther (2011) 1.01
Histone deacetylase inhibitors and cell death. Cell Mol Life Sci (2014) 1.00
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell (2016) 0.98
Novel therapeutic agents for cutaneous T-Cell lymphoma. J Hematol Oncol (2012) 0.98
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol (2011) 0.98
Macrocyclic histone deacetylase inhibitors. Curr Top Med Chem (2010) 0.98
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol (2010) 0.96
Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics (2015) 0.96
Chemotherapy-associated renal dysfunction. Nat Rev Nephrol (2009) 0.95
Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol Appl Pharmacol (2012) 0.95
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des (2013) 0.95
Discovery and activity profiling of thailandepsins A through F, potent histone deacetylase inhibitors, from Burkholderia thailandensis E264. Medchemcomm (2012) 0.95
Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms. PLoS One (2013) 0.95
The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis. J Biol Chem (2012) 0.94
New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 0.94
Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. AIDS (2013) 0.94
Small-molecule blocks malignant astrocyte proliferation and induces neuronal gene expression. Differentiation (2011) 0.94
Targeting histone deacetylases for the treatment of disease. J Cell Mol Med (2008) 0.94
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol Oncol (2014) 0.94
New insights into the genetic organization of the FK228 biosynthetic gene cluster in Chromobacterium violaceum no. 968. Appl Environ Microbiol (2010) 0.94
Flexibility of Catalytic Zinc Coordination in Thermolysin and HDAC8: A Born-Oppenheimer ab initio QM/MM Molecular Dynamics Study. J Chem Theory Comput (2009) 0.94
Vascular histone deacetylation by pharmacological HDAC inhibition. Genome Res (2014) 0.94
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One (2013) 0.93
A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PLoS One (2010) 0.93
Development of histone deacetylase inhibitors as therapeutics for neurological disease. Future Neurol (2009) 0.93
The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery. EMBO Rep (2009) 0.93
Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J Med Chem (2012) 0.93
Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain. Bioorg Med Chem Lett (2013) 0.93
Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer. Neoplasia (2014) 0.93
HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J (2016) 0.93
Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLoS Biol (2014) 0.93
The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer. Front Oncol (2014) 0.92
Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol (2008) 0.92
Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol (2013) 0.92
Targeting the epigenome with bioactive food components for cancer prevention. J Nutrigenet Nutrigenomics (2012) 0.91
Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Relat Cancer (2011) 0.91
Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. Neuro Oncol (2011) 0.91
Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease. Pharmacol Ther (2013) 0.90
Evolving therapies and FAK inhibitors for the treatment of cancer. Anticancer Agents Med Chem (2010) 0.90
Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem (2010) 0.90
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes. J Med Chem (2011) 0.90
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clin Cancer Res (2011) 0.90
Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol (2014) 0.90
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer (2014) 0.89
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. Cell Death Differ (2013) 0.89
Immune effectors required for the therapeutic activity of vorinostat. Oncoimmunology (2013) 0.89
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med (2011) 3.77
Perioperative complications of posterior lumbar decompression and arthrodesis in older adults. J Bone Joint Surg Am (2003) 3.75
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol (2010) 3.49
Shock-synthesized hexagonal diamonds in Younger Dryas boundary sediments. Proc Natl Acad Sci U S A (2009) 3.33
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist (2003) 3.28
Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol (2004) 3.18
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist (2009) 3.18
End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol (2003) 2.98
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res (2007) 2.94
Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst (2011) 2.74
Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med (2012) 2.69
Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res (2002) 2.56
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist (2003) 2.53
Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res (2007) 2.47
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res (2004) 2.43
Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist (2009) 2.37
Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res (2004) 2.24
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist (2007) 2.17
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res (2006) 2.07
Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst (2004) 2.07
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) (2009) 2.06
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res (2002) 2.06
Lumbar fusion outcomes stratified by specific diagnostic indication. Spine J (2008) 1.97
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist (2007) 1.94
Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res (2005) 1.93
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res (2008) 1.82
FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist (2005) 1.81
Genetic analysis of early holocene skeletal remains from Alaska and its implications for the settlement of the Americas. Am J Phys Anthropol (2007) 1.69
FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist (2005) 1.66
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) (2009) 1.63
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res (2007) 1.62
Are preoperative health-related quality of life scores predictive of clinical outcomes after lumbar fusion? Spine (Phila Pa 1976) (2009) 1.56
Treatment of pyogenic vertebral osteomyelitis with anterior debridement and fusion followed by delayed posterior spinal fusion. Spine (Phila Pa 1976) (2004) 1.55
U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist (2013) 1.52
Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013. Cancer (2014) 1.51
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist (2008) 1.49
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res (2010) 1.46
FDA drug approval summary: panitumumab (Vectibix). Oncologist (2007) 1.44
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res (2012) 1.41
Surgical management of adjacent level degeneration following lumbar spine fusion. Orthopedics (2002) 1.41
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist (2007) 1.38
FDA drug approval summaries: pemetrexed (Alimta). Oncologist (2004) 1.37
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res (2005) 1.36
RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age. Spine (Phila Pa 1976) (2008) 1.35
The perioperative cost of Infuse bone graft in posterolateral lumbar spine fusion. Spine J (2007) 1.34
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res (2012) 1.31
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res (2013) 1.31
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol (2007) 1.29
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res (2003) 1.29
FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist (2007) 1.29
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res (2005) 1.28
Posterolateral lumbar spine fusion with INFUSE bone graft. Spine J (2006) 1.27
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res (2013) 1.27
Clinical outcomes in older patients after posterolateral lumbar fusion. Spine J (2007) 1.25
FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist (2010) 1.25
FDA drug approval summaries: oxaliplatin. Oncologist (2004) 1.25
Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist (2010) 1.25
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist (2010) 1.24
Native American mtDNA prehistory in the American Southwest. Am J Phys Anthropol (2003) 1.21
FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol (2007) 1.20
Perioperative complications of lumbar instrumentation and fusion in patients with diabetes mellitus. Spine J (2003) 1.19
Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion. Spine (Phila Pa 1976) (2005) 1.19
FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist (2008) 1.17
Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res (2008) 1.17
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol (2007) 1.16
Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res (2003) 1.12
The structure of diversity within New World mitochondrial DNA haplogroups: implications for the prehistory of North America. Am J Hum Genet (2002) 1.12
FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist (2005) 1.12
U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res (2014) 1.12
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park) (2007) 1.11